BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
Taking everything into account, BMRN scores 7 out of 10 in our fundamental rating. BMRN was compared to 565 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. BMRN is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make BMRN a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
In multiple years BMRN reported negative net income over the last 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BMRN (4.70%) is better than 95.01% of its industry peers.
Looking at the Return On Equity, with a value of 5.95%, BMRN belongs to the top of the industry, outperforming 94.83% of the companies in the same industry.
BMRN has a Return On Invested Capital of 5.27%. This is amongst the best in the industry. BMRN outperforms 94.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROIC | 5.27% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BMRN has a better Profit Margin (11.71%) than 95.54% of its industry peers.
BMRN's Profit Margin has declined in the last couple of years.
BMRN has a Operating Margin of 14.88%. This is amongst the best in the industry. BMRN outperforms 95.54% of its industry peers.
BMRN has a better Gross Margin (78.95%) than 86.27% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
BMRN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 5.92. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.92, BMRN belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
BMRN has a debt to FCF ratio of 1.98. This is a very positive value and a sign of high solvency as it would only need 1.98 years to pay back of all of its debts.
BMRN has a Debt to FCF ratio of 1.98. This is amongst the best in the industry. BMRN outperforms 95.19% of its industry peers.
BMRN has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.11, BMRN is not doing good in the industry: 65.24% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 1.98 | ||
| Altman-Z | 5.92 |
ROIC/WACC0.53
WACC10.01%
2.3 Liquidity
A Current Ratio of 4.27 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Current ratio (4.27) which is in line with its industry peers.
BMRN has a Quick Ratio of 2.62. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.62, BMRN is not doing good in the industry: 68.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 127.27% over the past year.
The earnings per share for BMRN have been decreasing by -40.67% on average. This is quite bad
The Revenue has grown by 19.14% in the past year. This is quite good.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5YN/A
EPS Q2Q%161.9%
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Sales Q2Q%28.28%
3.2 Future
BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.08% yearly.
BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.86% yearly.
EPS Next Y120.5%
EPS Next 2Y79.23%
EPS Next 3Y62.26%
EPS Next 5Y49.08%
Revenue Next Year16.84%
Revenue Next 2Y13.19%
Revenue Next 3Y12.14%
Revenue Next 5Y11.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 36.26, the valuation of BMRN can be described as expensive.
Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.65% of the companies in the same industry.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (28.96), we can say BMRN is valued slightly more expensively.
With a Price/Forward Earnings ratio of 20.79, BMRN is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.47% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, BMRN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.26 | ||
| Fwd PE | 20.79 |
4.2 Price Multiples
95.19% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.19 | ||
| EV/EBITDA | 21.5 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 62.26% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y79.23%
EPS Next 3Y62.26%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (11/21/2024, 6:05:25 PM)
After market: 63.45 0 (0%)63.45
+0.89 (+1.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.09B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.26 | ||
| Fwd PE | 20.79 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.3
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.7% | ||
| ROE | 5.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 14.88% | ||
| PM (TTM) | 11.71% | ||
| GM | 78.95% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.27 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)127.27%
EPS 3Y-40.67%
EPS 5Y
EPS Q2Q%
EPS Next Y120.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.14%
Revenue growth 3Y9.15%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y